Wuzi Yanzong Pill relieves CPZ-induced demyelination by improving the microenvironment in the brain
Yan-Rong Li,
Meng-Ying Sun,
Wei Hang,
Qi Xiao,
Hui-Jie Fan,
Lu Jia,
Xiao-Ming Jin,
Bo Zhang,
Bao-Guo Xiao,
Cun-Gen Ma,
Zhi Chai
Affiliations
Yan-Rong Li
Shanxi Key Laboratory of Innovative Drug for the Treatment of Serious Diseases Basing on the Chronic Inflammation/Neurobiology Research Center, Shanxi University of Chinese Medicine, Jinzhong, Shanxi 030619, China
Meng-Ying Sun
Shanxi Key Laboratory of Innovative Drug for the Treatment of Serious Diseases Basing on the Chronic Inflammation/Neurobiology Research Center, Shanxi University of Chinese Medicine, Jinzhong, Shanxi 030619, China
Wei Hang
Shanxi Key Laboratory of Innovative Drug for the Treatment of Serious Diseases Basing on the Chronic Inflammation/Neurobiology Research Center, Shanxi University of Chinese Medicine, Jinzhong, Shanxi 030619, China
Qi Xiao
Shanxi Key Laboratory of Innovative Drug for the Treatment of Serious Diseases Basing on the Chronic Inflammation/Neurobiology Research Center, Shanxi University of Chinese Medicine, Jinzhong, Shanxi 030619, China
Hui-Jie Fan
Shanxi Key Laboratory of Innovative Drug for the Treatment of Serious Diseases Basing on the Chronic Inflammation/Neurobiology Research Center, Shanxi University of Chinese Medicine, Jinzhong, Shanxi 030619, China
Lu Jia
Shanxi Key Laboratory of Innovative Drug for the Treatment of Serious Diseases Basing on the Chronic Inflammation/Neurobiology Research Center, Shanxi University of Chinese Medicine, Jinzhong, Shanxi 030619, China
Xiao-Ming Jin
Department of Anatomy and Cell Biology, Department of Neurological Surgery, Spinal Cord and Brain Injury Research Group, Stark Neurosciences Research Institute. Indiana University School of Medicine, Indianapolis, IN 46202, United States
Bo Zhang
Health Commission of Shanxi Province, Taiyuan, Shanxi 030013, China
Bao-Guo Xiao
Huashan Hospital, Fudan University, Shanghai 200025, China
Cun-Gen Ma
Shanxi Key Laboratory of Innovative Drug for the Treatment of Serious Diseases Basing on the Chronic Inflammation/Neurobiology Research Center, Shanxi University of Chinese Medicine, Jinzhong, Shanxi 030619, China; Institute of Brain Science, Shanxi Datong University, Datong, Shanxi 037009, China; Corresponding author.
Zhi Chai
Shanxi Key Laboratory of Innovative Drug for the Treatment of Serious Diseases Basing on the Chronic Inflammation/Neurobiology Research Center, Shanxi University of Chinese Medicine, Jinzhong, Shanxi 030619, China; Corresponding author.
Ethnopharmacology relevance: Wuzi Yanzong Pill (WYP), a well-known prescription for invigorating the kidney and essence, which is widely used to treat infertility such as oligoasthenospermia. Studies have shown that WYP can be used to treat neurological diseases, but its therapeutic effects and mechanisms for multiple sclerosis (MS) remain unclear. Aim of the study: Based on the establishment of Cuprizone (CPZ)-induced demyelination model, this study determined the effect of WYP on remyelination by detecting changes in the microenvironment of the central nervous system. Materials and methods: C57BL/6 mice were divided into three groups. The CPZ group and CPZ + WYP group were fed with 0.2% CPZ feed, and the control group was fed normal feed, for 6 weeks. At the end of the second week, the CPZ + WYP group was gavaged with WYP solution (16 g/kg/d), and the other two groups were gavaged with normal saline twice a day with an interval of 12 h each time, for 4 weeks. Forced swimming and elevated plus maze were used to detect changes in anxiety and depression before and after treatment. Luxol fast blue staining and the expression of MBP were used to evaluate the demyelination of the brain. Western blot was used to detect the expression of microglia and their subtype markers Iba-1, Arg-1, iNOS, the expression of neurotrophic factors BDNF, GDNF, CNTF, and the expression of oligodendrocyte precursor cells NG2. ELISA detected the content of IL-6, IL-1β, IL-10, TGF-β, BDNF, GDNF, CNTF in the brain. The distribution of Iba-1 in the corpus callosum was observed by immunofluorescence. Results: The results showed that on the basis of improving mood abnormalities and demyelination, WYP reduced the protein content of Iba-1 and iNOS, increased the protein content of Arg-1, and reduce accumulation of microglia in the corpus callosum. In addition, WYP reduced the secretion of IL-6 and IL-1β while promoting the secretion of IL-10 and TGF-β. After WYP intervention treatment, the levels of neurotrophic factors BDNF, GDNF, CNTF increased. Due to the improvement of inflammatory and nutritional environment in the CNS, promoting the proliferation of NG2 oligodendrocyte, increased the expression of MBP, and repairing myelin sheath. Conclusion: Our results indicated that WYP promoted the proliferation and development of oligodendrocytes by improving the CNS microenvironment, effectively alleviating demyelination.